What is Cytokinetics?
Cytokinetics is a biopharmaceutical company headquartered in South San Francisco, California. It specializes in the discovery, development, and commercialization of innovative therapies aimed at treating diseases characterized by muscle performance decline. Founded by leading experts in muscle biology, the company leverages its deep scientific understanding to create first-in-class muscle activators and next-in-class muscle inhibitors. Its therapeutic focus targets a range of debilitating conditions where compromised muscle function significantly impacts patient quality of life.
How much funding has Cytokinetics raised?
Cytokinetics has raised a total of $222.7M across 3 funding rounds:
Stock Offering
$89.7M
Stock Offering
$33M
Other Financing Round
$100M
Stock Issuance/Offering (2004): $89.7M with participation from Goldman Sachs & Co.
Stock Issuance/Offering (2006): $33M led by Red Abbey Venture Partners and Federated Kaufmann
Other Financing Round (2017): $100M supported by Royalty Pharma
Key Investors in Cytokinetics
Goldman Sachs & Co.
Goldman Sachs & Co. is a prominent global investment banking firm, known for its extensive involvement in capital markets, underwriting, and strategic advisory services, likely providing significant financial backing and market expertise to Cytokinetics.
Royalty Pharma
Royalty Pharma is a key player in pharmaceutical financing, specializing in royalty-based investments, suggesting a strategic partnership focused on the future revenue streams of Cytokinetics' drug candidates.
Red Abbey Venture Partners
Red Abbey Venture Partners, an administrative services company supporting venture capital partnerships, likely provided early-stage backing and operational support, indicating a focus on nurturing emerging biotechnology ventures.
What's next for Cytokinetics?
The recent major strategic investment in Cytokinetics, amounting to $100M, positions the company for accelerated growth and the advancement of its therapeutic pipeline. This capital infusion, contributing to the overall $222.7M in financing, is expected to fuel further research and development, clinical trials, and potential commercialization efforts for its novel muscle activators and inhibitors. The company's focus on debilitating muscle diseases suggests a strategic expansion into key therapeutic areas, aiming to bring impactful treatments to patients worldwide. This significant backing indicates strong investor confidence in Cytokinetics' scientific approach and market potential.
See full Cytokinetics company page
